Inada, Ken
Saito, Yoshitaka
Baba, Kenji
Fukui, Daisuke
Masuda, Yuriko
Inoue, Sachie
Masuda, Takahiro
Funding for this research was provided by:
Sumitomo Pharma Co. Ltd.
Article History
Received: 22 September 2023
Accepted: 21 December 2023
First Online: 3 January 2024
Declarations
:
: No ethics review was necessary for this study because it was a secondary analysis of an anonymous patient database.
: Not applicable.
: Ken Inada received personal fees from Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, MSD, Nipro, Novartis, Otsuka, Pfizer, Shionogi, Sumitomo Pharma, Yoshitomiyakuhin, and Viatris, and he received research grant support from Mochida and Sumitomo pharma. Yoshitaka Saito has no conflict of interest.Takahiro Masuda, Kenji Baba, and Daisuke Fukui are full-time employees of Sumitomo Pharma Co. Ltd.Sachie Inoue and Yuriko Masuda are full-time employees of CRECON Medical Assessment Inc. CRECON Medical Assessment was paid by Sumitomo Pharma Co. Ltd. to conduct analyses for the study.